Stockreport

betibeglogene autotemcel (beti-cel) One-Time Gene Therapy for ß-thalassemia Continues to Demonstrate Durable Efficacy Across Pediatric and Adult Patient Populations and All Genotypes in Da...

bluebird bio, Inc.  (BLUE) 
Last bluebird bio, inc. earnings: 2/18 04:05 pm Check Earnings Report
US:NASDAQ Investor Relations: investor.bluebirdbio.com/investor-overview
PDF With 51 patients enrolled, data from the long-term follow-up study (LTF-303) show that all patients treated with beti-cel who achieve transfusion independence (TI) remai [Read more]